A Randomized Controlled Basket Study for Evaluating Immunomodulatory Interventions in Post-Acute Sequelae of SARS-CoV-2 InfEction (RISE)
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 632
- 试验地点
- 1
- 主要终点
- Inflammatory Cardiac Involvement symptom cluster: cardiac magnetic resonance (CMR) indicators
研究概览
简要总结
This study is a prospective, randomized controlled, basket trial. Patients diagnosed with Post-Acute Sequelae of SARS-CoV-2 Infection who meet the inclusion and exclusion criteria are recruited and divided into three symptom clusters: Inflammatory Cardiac involvement symptoms cluster, cough symptoms cluster and fatigue symptoms cluster. Each symptom cluster is randomly divided into an experimental group and a control group, Patients who do not accept treatment can be included in the observational cohort. Subjects in the experimental group receive immunomodulatory interventions plus conventional treatment, while subjects in the control group receive conventional treatment only. Subjects in each symptom cluster undergo clinical medical record data collection, laboratory tests, and imaging examinations at specified time points, as well as records of adverse events.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥18 years;
- •Post-infection with SARS-CoV-2 for more than 3 months and meets the World Health Organization (WHO) definition of Long COVID;
- •Symptom criteria: Meet the inclusion and exclusion criteria for each symptom cluster;
- •Fertile female subjects are not breastfeeding or pregnant at the time of enrollment (negative urine pregnancy test);
- •Willing and able to provide informed consent, complete surveys, clinical assessments, and all necessary follow-up visits;
- •Symptom Cluster Inclusion Criteria:
- •Inflammatory Cardiac Involvement Symptom Cluster
- •Age: 18-75 years old;
- •Presence of cardiac symptoms at the time of enrollment (e.g., Chest tightness after physical activity, chest pain, difficulty breathing, palpitations, fatigue, etc.);
- •CMR shows the following abnormal findings based on any of the following criteria:
- •a) Native T1 increase ≥ 1130 milliseconds at 3.0 T (or an increase of 1030 milliseconds at 1.5 T) and/or;
- •b) Native T2 ≥ 39.5 milliseconds at 3.0 T (or 49.5 milliseconds at 1.5 T) and/or;
- •c) Presence of non-ischemic myocardial and pericardial late gadolinium enhancement and/or;
- •d) Left ventricular ejection fraction ≥ 40% and ≤50%.
- •Cough Symptom Cluster
- •Clinical assessment of cough according to ACCP guidelines indicates no cough caused by other diseases such as COPD, asthma, chronic bronchitis, gastroesophageal reflux, bronchiectasis, etc.;
- •Chest X-ray or CT scan shows no abnormalities that could lead to cough or other serious lung diseases;
- •FENO ≥25 ppb, or the proportion of eosinophils in sputum cytology ≥2.5%; or the blood eosinophil count >0.3×10⁹/L.
- •Fatigue Symptom Cluster
- •Fatigue Severity Scale (FSS) average score ≥ 4;
- •Any inflammatory marker (CRP, ESR, PCT, ferritin, IL-6, TNFα) is above the upper limit of normal.
排除标准
- •Known SARS-CoV-2 infection within 3 months prior to the date of informed consent signature;
- •Systemic fungal infection and active infections that cannot be controlled by anti-infective agents;
- •Current or recent (within the last 10 weeks) use of glucocorticoids, other immunosuppressants, or biologic agents;
- •Known allergy/sensitivity or any hypersensitivity reaction to the study intervention or control components;
- •Known contraindications to the study intervention;
- •Any persistent central nervous system disorders, psychiatric illnesses, chronic respiratory or cardiac diseases, Underlying diseases (poorly controlled diabetes, poorly controlled hypertension, peripheral edema, cataracts or glaucoma, peptic ulcer disease, femoral head necrosis, low bone density, or osteoporosis);
- •For female participants: pregnant or breastfeeding at screening, or expecting to become pregnant during the study period; women of childbearing age who are unwilling to use effective contraceptive measures (defined as PEARL index <1, such as birth control pills, intrauterine devices);
- •Known alcohol, drug, or chemical abuse;
- •Currently participating in another clinical trial;
- •Deemed ineligible to participate in this study by the investigator's assessment.
- •Symptom Cluster Exclusion Criteria:
- •Inflammatory Cardiac Involvement Symptom Cluster
- •Past medical history or cardiac magnetic resonance (CMR) evidence indicating significant cardiac disease, including:
- •a) Known left ventricular ejection fraction (LVEF) <40% indicating cardiac dysfunction;
- •b) Congestive heart failure (New York Heart Association Class III-IV);
- •c) Ongoing treatment for heart failure (including HFrEF and HFpEF);
- •d) Confirmed ischemic heart disease, peripheral artery disease, and/or cerebrovascular disease;
- •e) Persistent or permanent atrial fibrillation or significant arrhythmias;
- •f) Congenital or clinically relevant valvular heart disease (moderate or severe);
- •g) Specific cardio myopathies (hypertrophic, hypertensive heart disease, amyloidosis, previous myocarditis, non-ischemic dilated cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, non-compacted cardiomyopathy, etc.);
- •Contraindications for contrast-enhanced cardiac magnetic resonance (CMR) imaging, such as: use of implanted devices not compatible with MRI; known allergy to gadolinium-based contrast agents (CBGA);
- •Patients with structural heart disease or incidental arrhythmias detected on cardiac magnetic resonance imaging will be advised to consult their physicians.
- •Cough Symptom Cluster
- •Current smoker or having quit smoking for less than 6 months;
- •Intolerance to pulmonary function testing and/or FeNO;
- •Chest CT showing acute pulmonary infection-related diseases;
- •Forced expiratory volume in 1 second (FEV1) / Forced vital capacity (FVC) ratio less than 60%;
- •Currently taking or having used angiotensin-converting enzyme inhibitors (ACEI) within the past 3 months of screening;
- •Received any relevant traditional Chinese or Western medical treatment within the last month.
- •Fatigue Symptom Cluster
- •Received any relevant traditional Chinese or Western medical treatment within the last month, taking sedatives, hypnotics, melatonin, or antidepressants;
- •Known previous diagnosis of myalgic encephalomyelitis/chronic fatigue syndrome unrelated to SARS-CoV-2 infection;
- •Known previous autonomic dysfunction unrelated to SARS-CoV-2 infection;
- •Fatigue caused by metabolism-related diseases (such as hyperthyroidism or hypothyroidism, malnutrition) that developed following SARS-CoV-2 infection.
研究组 & 干预措施
Inflammatory Cardiac Involvement symptom cluster - immunomodulatory intervention
干预措施: Prednisone (Drug)
Inflammatory Cardiac Involvement symptom cluster - immunomodulatory intervention
干预措施: Vitamin C combined with Coenzyme Q10 oral treatment (Drug)
Inflammatory Cardiac Involvement symptom cluster
干预措施: Vitamin C combined with Coenzyme Q10 oral treatment (Drug)
Cough symptom cluster - immunomodulatory intervention
干预措施: Budesonide/Formoterol (Drug)
Cough symptom cluster - immunomodulatory intervention
干预措施: Montelukast tablets oral treatment (Drug)
Cough symptom cluster
干预措施: Montelukast tablets oral treatment (Drug)
Fatigue symptom cluster - immunomodulatory intervention
干预措施: Prednisone (Drug)
Fatigue symptom cluster - immunomodulatory intervention
干预措施: Vitamin C combined with Coenzyme Q10 oral treatment (Drug)
Fatigue symptom cluster
干预措施: Vitamin C combined with Coenzyme Q10 oral treatment (Drug)
结局指标
主要结局
Inflammatory Cardiac Involvement symptom cluster: cardiac magnetic resonance (CMR) indicators
时间窗: 4 weeks
Assessing the difference in changes in cardiac magnetic resonance (CMR) indicators \[left ventricular ejection fraction, late gadolinium enhancement (LGE), and T1 and T2 mapping values (in milliseconds)\] from baseline between the experimental and control groups.
Cough symptom cluster: Leicester Cough Questionnaire (LCQ) scale scores
时间窗: 8 weeks
Assessing the difference in changes in the Leicester Cough Questionnaire (LCQ) scale scores from baseline. The total score range of the LCQ is from 3 to 21 points, with higher scores indicating a lesser impact of cough on the patient's life.
Fatigue symptom cluster: Fatigue Severity Scale (FSS) scale scores
时间窗: 4 weeks
Assessing the difference in changes in the Fatigue Severity Scale (FSS) scale scores from baseline. The total score range of the FSS is from 9 to 63 points, with higher scores indicating a greater severity of fatigue.
次要结局
- Inflammatory Cardiac Involvement symptom cluster: other relevant cardiac magnetic resonance (CMR) indicators(4 weeks)
- Inflammatory Cardiac Involvement symptom cluster: VO2max(At baseline, 4 weeks)
- Inflammatory Cardiac Involvement symptom cluster: Kansas City Cardiomyopathy Questionnaire (KCCQ) scores(At baseline, 4, 8, 12, and 24 weeks)
- Inflammatory Cardiac Involvement symptom cluster: Change in cTNT Levels(At baseline, 4, 8, 12 and 24 weeks)
- Inflammatory Cardiac Involvement symptom cluster: the proportion of patients experiencing heart failure and major adverse cardiac events (MACE)(From baseline to 52 weeks)
- EuroQoL 5-Dimension 5-Level (EQ-5D-5L) questionnaire scores(At baseline, 4, 8, 12 and 24 weeks)
- Pittsburgh Sleep Quality Index (PSQI) scores(At baseline 4, 8, 12, and 24 weeks)
- Generalized Anxiety Disorder-7 (GAD-7)(At baseline, 4, 8, 12 and 24 weeks)
- Patient Health Questionnaire-9 (PHQ-9) depression symptom cluster scores(At baseline, 4, 8, 12 and 24 weeks)
- Cough symptom cluster: pulmonary function and fractional exhaled nitric oxide (FeNO) levels(At baseline and 8 weeks)
- Cough symptom cluster: Visual Analogue Scale (VAS)(At baseline 4, 8 and 12 weeks)
- Fatigue symptom cluster: Visual Analogue Scale (VAS)(At baseline, 4, 8, and 12 weeks)
- Change in proBNP Levels(Baseline, 4, 8, 12, 24 weeks)
- Change in Angiotensin II Levels(Baseline, 4, 8, 12, 24 weeks)
- Change in Ferritin Levels(Baseline, 4, 8, 12, 24 weeks)
- Change in IL-6 Levels(Baseline, 4, 8, 12, 24 weeks)
- Change in hsCRP Levels(Baseline, 4, 8, 12, 24 weeks)